INBRAIN Neuroelectronics
High density and high resolution graphene intelligent neural systems for BCI therapeutics *FDA Breakthrough Designation*
126 employees · est. 2020 · Barcelona, Spain
MitoRx Therapeutics
Developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity.
17 employees · est. 2021 · Oxford, United Kingdom
INBRAIN Neuroelectronics is the older company (2020 vs 2021); INBRAIN Neuroelectronics is the larger of the two.
Side-by-Side Comparison
| Metric | INBRAIN Neuroelectronics | MitoRx Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2020 older | 2021 |
| Headquarters | ||
| Headquarters | Barcelona, Spain | Oxford, United Kingdom |
| Employees | ||
| Employees | 126 larger | 17 |
| Industry | ||
| Industry | AI, Biotechnology, Consumer Electronics | Biotechnology, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Series B | Seed |
| Total Funding | ||
| Total Funding | $92.95M | $4.00M |
| Funding Rounds | ||
| Funding Rounds | 9 | 3 |
| Services | ||
| Services | Development of graphene-based brain-computer interfaces, Real-time personalized neurotherapy, Neural signal decoding and modulation, Collaborations with academic and industry leaders within neuroscience and AI sectors | development of obesity treatments, restoration of mitochondrial metabolism, therapy for insulin resistance |
| Target Customers | ||
| Target Customers | Patients with brain disorders, Healthcare providers specializing in neurology, Neurosurgeons, Research institutions in neuroscience, Biopharmaceutical companies | individuals with high-risk obesity, patients with metabolic disorders, healthcare providers focusing on obesity |
| Taxonomy | ||
| Taxonomy | Graphene-based Technology, Brain-Computer Interface, Neuroelectronics, Precision Neurology, AI-driven Therapeutics, Neural Modulation, Real-time Monitoring, Personalized Therapy, Parkinson's Disease Treatment, Epilepsy Management, Stroke Rehabilitation, Peripheral Nerve Applications, Systemic Disease Applications, Bioelectronics, Nanotechnology | Biotech, Rare Disease, Neuromuscular Disease, Metabolic Disease, Neurodegenerative Disease, Mitochondrial Dysfunction, Drug Discovery, Mitochondrial Disease, Duchenne, Mitochondria, Muscular Dystrophy, Pre-clinical Stage, Therapeutics, Novel, First-in-class |
| Website | ||
| Website | inbrain-neuroelectronics.com | mitorxtherapeutics.com |
About INBRAIN Neuroelectronics
INBRAIN Neuroelectronics, founded in 2020, is at the forefront of developing high-density and high-resolution graphene neural systems aimed at both central and peripheral neuroelectronic applications. The company, based in Spain, is pioneering a new era in precision neurology with its innovative app...
About MitoRx Therapeutics
MitoRx Therapeutics is a pre-clinical stage rare disease biotech company founded in 2016 with the mission to arrest the progression of degenerative diseases driven by mitochondrial dysfunction. Their focus lies on neuromuscular disease, metabolic disease, and neurodegenerative disease. The company,...
We will tell you when either one moves
BounceWatch watches INBRAIN Neuroelectronics and MitoRx Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at INBRAIN Neuroelectroni... and MitoRx Therapeutics — by email.
Frequently Asked Questions
Compare INBRAIN Neuroelectronics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at INBRAIN Neuroelectronics on 2 Sep 2026, and MitoRx Therapeutics on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.